Limits...
ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Ries S, Korn WM - Br. J. Cancer (2002)

Bottom Line: Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics.The main advantages of employing replication-competent viruses are achievement of tumour selective killing and amplification of their oncolytic potential within the tumour mass.In this review, we describe the development of ONYX-015, one of the first and most advanced replication-competent viruses for cancer therapy.

View Article: PubMed Central - PubMed

Affiliation: MediGene AG, Lochhamer Strasse 11, 82152 Martinsried, Germany.

ABSTRACT
Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics. The main advantages of employing replication-competent viruses are achievement of tumour selective killing and amplification of their oncolytic potential within the tumour mass. In this review, we describe the development of ONYX-015, one of the first and most advanced replication-competent viruses for cancer therapy. We discuss the molecular biology of this therapeutic approach and the interesting results obtained with this virus in clinical trials.

Show MeSH

Related in: MedlinePlus

The interaction of adenovirus proteins with the Rb and p53 tumour suppressor pathways. Activating (→) and inactivating effects are indicated (T on side) as well as protein phosphorylation events (P in circle).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2746528&req=5

fig1: The interaction of adenovirus proteins with the Rb and p53 tumour suppressor pathways. Activating (→) and inactivating effects are indicated (T on side) as well as protein phosphorylation events (P in circle).

Mentions: Tumorigenesis is a multistep process in which mutations in genes involved in cell cycle control and apoptosis accumulate over time (Christofori and Hanahan, 1994; Vogelstein and Kinzler, 1993). Inactivation of tumour suppressors and activation of proto-oncogenes leads to uncontrolled growth and cell division, hallmarks of tumour development. It is now well established that there are common targets of mutation events in cancer development. For example, many tumours have defects in a pathway controlling cell cycle progression that includes cyclin D1, cdk4, p16INK4a, and the retinoblastoma protein (Rb; Figure 1Figure 1


ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Ries S, Korn WM - Br. J. Cancer (2002)

The interaction of adenovirus proteins with the Rb and p53 tumour suppressor pathways. Activating (→) and inactivating effects are indicated (T on side) as well as protein phosphorylation events (P in circle).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2746528&req=5

fig1: The interaction of adenovirus proteins with the Rb and p53 tumour suppressor pathways. Activating (→) and inactivating effects are indicated (T on side) as well as protein phosphorylation events (P in circle).
Mentions: Tumorigenesis is a multistep process in which mutations in genes involved in cell cycle control and apoptosis accumulate over time (Christofori and Hanahan, 1994; Vogelstein and Kinzler, 1993). Inactivation of tumour suppressors and activation of proto-oncogenes leads to uncontrolled growth and cell division, hallmarks of tumour development. It is now well established that there are common targets of mutation events in cancer development. For example, many tumours have defects in a pathway controlling cell cycle progression that includes cyclin D1, cdk4, p16INK4a, and the retinoblastoma protein (Rb; Figure 1Figure 1

Bottom Line: Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics.The main advantages of employing replication-competent viruses are achievement of tumour selective killing and amplification of their oncolytic potential within the tumour mass.In this review, we describe the development of ONYX-015, one of the first and most advanced replication-competent viruses for cancer therapy.

View Article: PubMed Central - PubMed

Affiliation: MediGene AG, Lochhamer Strasse 11, 82152 Martinsried, Germany.

ABSTRACT
Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics. The main advantages of employing replication-competent viruses are achievement of tumour selective killing and amplification of their oncolytic potential within the tumour mass. In this review, we describe the development of ONYX-015, one of the first and most advanced replication-competent viruses for cancer therapy. We discuss the molecular biology of this therapeutic approach and the interesting results obtained with this virus in clinical trials.

Show MeSH
Related in: MedlinePlus